Eiko Lifesciences Ltd - 540204 - Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Statement on Deviation or Variation of Funds under Regulation Regulation 32 of SEBI (LODR)2015 Eiko Lifesciences Ltd - 540204 - Financial Results For Quarter And Nine Months Ended 31St December,2023
Financial Results for quarter and nine months ended 31st December,2023 Eiko Lifesciences Ltd - 540204 - Board Meeting Outcome for Outcome Of The Board Meeting
Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and amendments thereto, this is to inform that the Meeting of the Board of Directors of the Company held today i.e., on Thursday, 08th February, 2024, Board, inter-alia, considered and approved the Unaudited Financial Results for the Quarter and nine months ended 31st December,2023. The Statutory Auditors have carried out a 'Limited Review' of the Unaudited Financial Results for the Quarter and nine months ended 31st December 2023. Further, Pursuant to the Regulation 33 of the Listing Regulations, we are enclosing herewith a copy of the Unaudited Financial Results and Limited Review Report of the Statutory Auditors of the Company Eiko Lifesciences Ltd - 540204 - Outcome Of The Rights Issue Committee Meeting
Approved sending of a Reminder Notice to partly-paid up shareholders on which First and Final call Money remains unpaid Details enclosed Eiko Lifesciences Ltd - 540204 - Submission Of Revised Corporate Announcement As Per BSE E-Mail Dated 02Nd February, 2024
In response to the BSE e-mail dated 02nd February,2024, we are re-submitting the revised corporate announcement with necessary changes Eiko Lifesciences Ltd - 540204 - Intimation Of Right Issue Committee Meeting Of The Board Of Directors To Be Held On 08Th February,2024
Intimation of Right Issue Committee Meeting of the Board of Directors to be held on 08th February,2024 to discuss the matters relating to post First and Final Call Money Procedures and who failed to pay their First and Final Call Money Procedures and who failed to pay their first call money within due date. Eiko Lifesciences Ltd - 540204 - Board Meeting Intimation for Board Meeting Intimation For Considering Financial Results For The Quarter And Nine Months Ending 31St December, 2023
Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 ,inter alia, to consider and approve This is to inform you that as required under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of Board of Directors of the Company is scheduled to be held on Thursday, 08th February, 2024 inter-alia, to consider and approve the following: 1. The Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2023 2. Any other matter with the permission of the chair. Eiko Lifesciences Ltd - 540204 - Outcome Of Right Issue Committee Meeting Dated 25 January, 2024
1. To convert 3353121 partly paid rights equity shares to the eligible shareholders of the Company pursuant to payment made with respect to the First and Final Call issued by the Company 2. To make application to National Securities Depository Limited and Central Depository Services (India) Limited 3. To avail listing and trading approval from BSE Limited pursuant to conversion of partly paid up shares Eiko Lifesciences Ltd - 540204 - Business Update - Agreement With Vivacious Pharmatex Private Limited
We are pleased to update that our Company has officially entered into definitive business agreement with Vivacious Pharmatex Private Limited for developing and marketing of products under new segment i.e., Oleochemicals and allied business Eiko Lifesciences Ltd - 540204 - Board Meeting Outcome for Outcome Of The Board Meeting And Disclosure Regulation 30 Of SEBI ((Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we would like to inform you that the Board of Directors in their meeting held today has considered and approved the below transaction: Company ('ELL'') to enter into definitive business agreement with Vivacious Pharmatex Private Limited (VPPL) for Company's Growth and strategic positioning.